title: A multicentre study of a randomized therapeutic protocol in previously untreated patients with Ph-positive chronic myelogenous leukaemia: interferon alfa-2b and hydroxyurea with or without cytosine arabinoside , preliminary results.
authors.affiliation: Hôpital Jean Bernard La Milétrie, France.
authors.forename: F
authors.initials: F
authors.lastname: Guilhot
authors.forename: J P
authors.initials: JP
authors.lastname: Lamagnère
authors.forename: J L
authors.initials: JL
authors.lastname: Harousseau
authors.forename: H
authors.initials: H
authors.lastname: Tilly
authors.forename: P
authors.initials: P
authors.lastname: Casassus
authors.forename: N
authors.initials: N
authors.lastname: Ifrah
authors.forename: H
authors.initials: H
authors.lastname: Rochant
authors.forename: F
authors.initials: F
authors.lastname: Bauters
authors.forename: G
authors.initials: G
authors.lastname: Dine
authors.forename: J
authors.initials: J
authors.lastname: Tanzer
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage; D005260:Female; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage; D007370:Interferon Type I / Q000008:administration & dosage; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins
chemical_list: D007370:Interferon Type I; D011994:Recombinant Proteins; D003561:Cytarabine; D006918:Hydroxyurea